Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739696 | 0.92 | KIF11 (0.55) | KIF11KIF23AGTR1AGTR2 | |
| SCHEMBL5248554 | 0.90 | KIF11 (0.49) | KIF11KIF23MC4R | |
| SCHEMBL4859195 | 0.88 | KIF11 (0.54) | KIF11KIF23AGTR1AGTR2 | |
| SCHEMBL5246236 | 0.86 | KIF11 (0.52) | KIF11TLR7GNRHRKIF23MC4R | |
| SCHEMBL3961772 | 0.86 | KIF11 (0.67) | KIF11KIF23 | |
| SCHEMBL5246052 | 0.85 | TLR7 (0.43) | KIF11TLR7GNRHRSIGMAR1 | |
| SCHEMBL3865232 | 0.83 | KIF11 (0.60) | KIF11KIF23 | |
| SCHEMBL3887257 | 0.83 | KIF11 (0.75) | KIF11 | |
| SCHEMBL5740939 | 0.81 | KIF11 (0.47) | KIF11TLR7GNRHRKIF23MC4R | |
| SCHEMBL5246048 | 0.81 | KIF11 (0.44) | KIF11TLR7SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885TLR7 4050/4885GNRHR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.